The new Flash Glucose Monitoring System enables patients to wear the sensor for up to 14 days compared with the existing FreeStyle Libre System that was approved for 10-day wear. Abbott announced that ...
The Freestyle Libre 14 day is now the longest-lasting self-applied continuous glucose sensing technology available and allows the used to wear the sensor for up to 14 days with high accuracy. ABBOTT ...
Monitoring your blood sugar level no longer requires you to draw blood. The U.S. Food and Drug Administration (FDA) has approved a device that will bring diabetes patients into the 21st century of ...
Abbott Diabetes Care's Freestyle Libre Flash Glucose Monitoring System has been approved by the FDA. As well as finally bringing the system, which is already available in 39 other countries, home to ...
MISSISSAUGA, Ontario, Oct. 4, 2018 /CNW/ -- Abbott (NYSE: ABT) announced today the company has received the Health Canada license of its FreeStyle LibreLink mobile app for use with compatible iOS ...
ABBOTT PARK, Ill., Sept. 28, 2020 /PRNewswire/ -- Abbott (NYSE: ABT), the worldwide leader in continuous glucose monitoring (CGM) technology, 8 announced today it has secured CE Mark (Conformité ...
ABBOTT PARK, Ill., Sept. 3, 2014 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that it has received CE Mark (Conformite Europeenne) for its FreeStyle ® Libre Flash Glucose Monitoring System, a ...
6 July, 2017 — The wait for the latest glucose monitoring technology is over for New Zealand’s diabetes community, with the arrival of Abbott’s FreeStyle® Libre flash glucose monitoring system – a ...
MISSISSAUGA, ON, Aug. 8, 2024 /CNW/ -- Abbott (NYSE: ABT) today announced that the Government of Quebec's Régie de l'assurance maladie du Québec (RAMQ) published an update to its formulary that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback